Effects of nicorandil on receptor-mediated Ca2+ release and Ca2+ entry in vascular smooth muscle.
In a solution containing La3+, or one without Ca2+ (Ca2+-free) and containing 1.0 mM ethylene glycol bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), norepinephrine (NE)-induced transient contractions in rabbit aorta attributed to Ca2+ release are depressed 31 and 38%, respectively, by an approximate ED60 relaxing concentration of nicorandil (SG-75). In addition, after 15 min in a Ca2+-free, low-EGTA (0.01 mM) solution, plus D600 to eliminate any potential-dependent Ca2+ entry, NE elicits a similar phasic response that is attenuated 34% by SG-75. Apparently, this is primarily due to inhibition of Ca2+ release rather than to stimulation of rebinding, uptake, and/or extrusion of Ca2+ following release. For, when tissues initially exposed to a Ca2+-free, low-EGTA plus D600 solution with or without SG-75 and NE are then rinsed with the same solution for 20 min to remove SG-75 and/or NE and again exposed to NE there is only a small residual maintained response in tissues not exposed to SG-75. However, in tissues that have been exposed to SG-75 prior to NE, a measurable phasic response is elicited that is approximately 50% of control NE responses. When Ca2+ is added to a Ca2+-free, low-EGTA plus D600 solution after NE-induced Ca2+ release, a rapid and significant increase in tension ensues that is well maintained and is proposed to represent specific alpha-adrenoceptor-mediated Ca2+ entry. This NE-mediated, D600-insensitive Ca2+ entry is readily inhibited or relaxed by SG-75.(ABSTRACT TRUNCATED AT 250 WORDS)
D000818:Animals; D002118:Calcium / Q000378:metabolism*; D004533:Egtazic Acid / Q000494:pharmacology; D005260:Female; D005711:Gallopamil / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000378:metabolism; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000494:pharmacology; D020108:Nicorandil; D009638:Norepinephrine / Q000502:physiology; D011817:Rabbits; D011956:Receptors, Cell Surface / Q000187:drug effects*; D014661:Vasoconstriction / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology*
D011956:Receptors, Cell Surface; D014665:Vasodilator Agents; D009536:Niacinamide; D020108:Nicorandil; D005711:Gallopamil; D004533:Egtazic Acid; D002118:Calcium; D009638:Norepinephrine